Genmab — August 2017
-
så skulle man lave en actelionmodel, hvor dara bliver splittet fra resten af Genmab. Men synergimæssigt er GEN rasende uinteressant da alle kommercielle rettigheder på dara/ofa er solgt fra og resten af pipelinen er voldsomt umoden
-
umiddelbart kan jeg ikke se andre købere end JJ til GEN
-
Prøvede Gilead hexa og duobody af i Hiv som et slags skalkeskjul for at se potentialet og så fandt de ud af at Car-T er bedre? Mener også Genmabs nuværende stadie er meget umodent og jeg tvivler en hel del på potentialet i tisotumab, håber jeg tager fejl dog.
-
Premarket: Kite +28%, Juno +20% og Bluebird +10%.
-
We need more fantasy like this - "Genmab A/S: Big US pharma could make a move after latest drug trial success" - https://wallstreetwires.com/genmab-big-us-pharma-make-move-latest-drug-trial-success/

-
Good to be back
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind